Latest publications Pål André Holme
Long-term efficacy and safety of damoctocog alfa pegol prophylaxis in patients with haemophilia A aged 12-<18 years at enrolment into PROTECT VIII
Acta Haematol (in press)
DOI 10.1159/000538702, PubMed 38599195
Elevated FVIII levels in hereditary hemorrhagic telangiectasia: Implications for clinical management
Laryngoscope Investig Otolaryngol, 9 (1), e1196
DOI 10.1002/lio2.1196, PubMed 38362186
Safety and efficacy of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A: Results of an interventional, post-marketing study
Haemophilia, 30 (2), 388-394
DOI 10.1111/hae.14930, PubMed 38229269